Tirbanibulin for Pediatric Warts
The Skin Center Dermatology Group · NCT06791525
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 8–18 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 4
- Target enrollment
- 10
- US sites recruiting
- 1
- Study start
- May 1, 2025
- Record last updated
- April 23, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Warts are common, benign skin lesions caused by the human papillomavirus (HPV). Treatment is challenging, particularly in the pediatric population, where standard modalities such as cryotherapy and intralesional immunotherapy are poorly tolerated. Existing topical treatments, such as imiquimod and 5-fluorouracil, have low efficacy and require prolonged use. Case reports suggest tirbanibulin ointment may provide an effective and well-tolerated alternative for pediatric warts. This study will evaluate the efficacy and safety of tirbanibulin ointment in treating pediatric hand warts.
Being studied: Tirbanibulin ointment 1%
Conditions: Warts Hand
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age 8-18
- Subject and their legally authorized representative must be able to understand and be willing to adhere to all protocol requirements and voluntarily sign and date informed consent and assent for minors.
- Subject is judged to be in good health as determined by the Principal Investigator, based upon the results of the screening assessments and medical history.
- Diagnosis of warts on the hands
- Wart count on the hands and 3-10
Exclusion Criteria
- Wart duration >2 years.
- More than 10 warts in non-hand areas.
- Total wart surface area on the hands bigger than 100 cm2
- Prior treatment failure with the following modalities:
- intralesional immunotherapy 2. intralesional bleomycin, 5-fluorouracil, methotrexate 3. intralesional cidofovir 5. Any over the counter, prescription topical, or in-office procedural wart treatment within 6 weeks of baseline (Day 1) 6. Known immuno-suppressed state due to disease or medication, medical treatment o 7. Known allergy to any component of the IP 8. Any conditions that, in the Principal Investigator's opinion, may interfere with the course of the study
Recruiting US locations
The Skin Center Dermatology Group
New City, NY 10956
Site contact: Eszter Friedman, Clinical Research Coordinator · 315-616-3706 · trial@skincenterderm.com
Study contacts (from the official record)
- Peter Friedman, MD, PhD · 8453520500 · drfriedman@skincenterderm.com